Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis-Reference-Cited by-同舟云学术

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

Published:2023-03-30 Issue:4 Volume:7 Page:e860
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Canales Miguel A.¹,Buchholz Thomas A.²,Bortolini Jaisson A.P.³,Fogliatto Laura M.⁴,Ishikawa Takayuki⁵,Izutsu Koji⁶,Salar Antonio⁷,Sharman Jeff P.⁸,Klingbiel Dirk⁹,Pokala Sunny⁹,Vorozheikina Ekaterina¹⁰,Trask Peter¹¹,Parreira Joana⁹,Hübel Kai¹²

Affiliation:

1. Hospital Universitario La Paz, Madrid, Spain

2. Scripps MD Anderson Cancer Center, San Diego, CA, USA

3. Centro de Pesquisas Oncologicas, Florianopolis, Brazil

4. Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

5. Kobe City Medical Center, General Hospital, Hyogo, Japan

6. National Cancer Center Hospital, Tokyo, Japan

7. Hospital del Mar, Barcelona, Spain

8. Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA

9. F. Hoffmann-La Roche Ltd, Basel, Switzerland

10. IQVIA Medical and Scientific Services, Moscow, Russia

11. Genentech, Inc., South San Francisco, CA, USA